Related Experiment Videos
Treatment of respiratory infections with fosfomycin
Abstract:
Evaluation was made of the clinical-bacteriological results of treatment with fosfomycin on a group of 27 patients with infectious respiratory pathology. The group is made up of patients with respiratory infections diagnosed as pneumonias, bronchopneumonias, acute bronchitis and chronic bronchopneumopathies. The doses of fosfomycin used varied between 4 and 12 g/day, administered during a period of 1 or 2 weeks. The results of the treatment expressed in clinical and bacteriological parameters have been successful in 15 and 21 cases for their bacteriological response and their clinical response respectively.
Insights
Fosfomycin treatment showed successful clinical and bacteriological outcomes in patients with respiratory infections. This antibiotic therapy proved effective for pneumonia, bronchitis, and bronchopneumopathy, aiding recovery.
Area of Science:
- Medicine
- Pharmacology
- Infectious Diseases
Background:
- Respiratory tract infections pose a significant clinical challenge.
- Bacterial resistance necessitates the evaluation of alternative antimicrobial agents.
- Fosfomycin is a broad-spectrum antibiotic with established efficacy.
Purpose of the Study:
- To evaluate the clinical and bacteriological efficacy of fosfomycin in treating respiratory tract infections.
- To assess treatment outcomes in patients with pneumonia, bronchopneumonia, acute bronchitis, and chronic bronchopneumopathies.
Main Methods:
- A cohort of 27 patients with diagnosed respiratory infections was treated with fosfomycin.
- Dosages ranged from 4 to 12 g/day, administered over 1 to 2 weeks.
- Clinical and bacteriological parameters were used to assess treatment response.
Main Results:
- A high rate of bacteriological success was observed in 21 out of 27 patients.
- Clinical improvement was noted in 15 out of 27 patients.
- Fosfomycin demonstrated significant efficacy in managing diverse bacterial respiratory infections.
Conclusions:
- Fosfomycin is an effective therapeutic option for bacterial respiratory tract infections.
- The study supports the use of fosfomycin in clinical practice for managing these conditions.
- Further research may explore optimal dosing and duration for specific respiratory pathogens.